Articles

San Fransisco, CA—An economic model designed to determine the cost of instituting a clinical pathway inmetastatic colorectal cancer (mCRC) showed that the costs associated with implementing such a pathway may outweigh any potential cost-savings it may provide, at least for the near-term, according to Tanya G.K. Bentley, PhD, PHAR LLC, Beverly Hills, CA, and colleagues.

The combined use of effective multidrug chemotherapy regimens and radiation over the past few decades has led to significant improvements in the prognosis of Hodgkin lymphoma, making achievement of a cure a clinical reality for the majority of patients.¹ With current therapies, long-term tumor control may be achieved in 70%-80% of patients.¹ However, a subset of patients do not respond to frontline therapy or relapses following initial response.

Nikhil Munshi believes caregivers should be informed about the newer medicines so they can be aware of potential side effects as well as medicine's responsibility to take a holistic approach to patients' lives post-treatment.

Nikhil Munshi believes caregivers should be informed about the newer medicines so they can be aware of potential side effects as well as medicine's responsibility to take a holistic approach to patients' lives post-treatment.